Influence of neoadjuvant chemotherapy on liver integrity and ischemic tolerance;Der Einfluss neoadjuvanter chemotherapie auf leberintegrität und ischämietoleranz

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 1, 2008, Pages 17-21

  Manekeller, Steffen ^a   Sioutis, M ^a   Hirner, A ^a   Minor, T ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Chemotherapy; Ischaemia; Liver metastases

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; FLUOROURACIL; FOLINIC ACID; GLUCOSE REGULATED PROTEIN 78; OXALIPLATIN; PLACEBO; PUMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BILE FLOW; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; LIVER FUNCTION; LIVER ISCHEMIA; LIVER METASTASIS; MALE; NONHUMAN; RAT; UPREGULATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHEMOTHERAPY, ADJUVANT; FLUOROURACIL; INJECTIONS, INTRAPERITONEAL; ISCHEMIC PRECONDITIONING; LIVER; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; ORGANOPLATINUM COMPOUNDS; PLACEBOS; RATS; RATS, WISTAR; REPERFUSION INJURY; TIME FACTORS;

EID: 39349109233     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963440     Document Type: Article

References (36)

1. Monga DK, O'conell MJ. Surgical adjuvant therapy for colorectal cancer: Current approaches and future directions. Ann Surg Oncol 2006; 13: 1021-1034
2. Manekeller S, Lauschke H, Tolba R et al. Palliative chemotherapy in colorectal cancer-Results of an inquiry. Chir Gastroenterol 2003; 19: 89-95
3. Kubicka S, Manns MP. Adjuvant chemotherapy in liver malignancy for improving operability. Chirurg 2001; 72: 759-764
4. Bechstein WO, Golling M. Standard surgical resection of colorectal liver metastases. Chirurg 2005; 76: 543-551
5. Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, Fluorouracil and Leukovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Cancer Treatment Group Phase II Study. J Clin Oncol 2005; 23: 9243-9249
6. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; Epub ahead of print
7. Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcome after preoperative chemotherapy with Fluorouracil plus Oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990
8. Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7
9. Golling M, Gog C, Woeste G et al. Colorectal cancer liver metastases-neoadjuvant concepts for preoperative downsizing. Zentralbl Chir 2006; 131: 140-147
10. Lorenz M, Sebler ES, Gog C et al. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir 2003; 128: 87-94
11. Langer B, Bleiberg H, Labianca R et al. Fluorouracil (FU) plus 1-leucovorin (1-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC) : results of the ENG 8EORTC/NCIC/CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002; 21: 49-149
12. Portier G, Rougier P, Milan C et al. Adjuvant systemic chemotherapy (CT) using 5-fluorouracil (FU) and folinic acid (FA) after resection of liver metastases (LM) from colorectal (CRC) origin. Results of an intergroup phase III study (trial FFCD-ACHBTH-AURC 9002). Proc Soc Clin Oncol 2002; 21: 133a
13. Virani S, Michaelson JS, Hutter MM et al. Morbidity and mortality after liver resection: Results of the patient safety and surgery study. J Am Coll Surg 2007; 204: 1284-1292
14. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-176
15. Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006; 31: 4954-4955
16. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2071
17. Pawlik TM, Olino K, Gleisner AL et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868
18. Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxalplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466
19. Sebagh M, Plasse M, Levi F et al. Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity? Ann Oncol 2005; 16: 331
20. Fernandez FG, Ritter J, Goodwin JW et al. Effect of steatohepatitis associated with Irinotecan or Oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200 (6): 845-853
21. Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with Oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg 2006; 202 (1): 199-200
22. Meric F, Patt YZ, Curley SA et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7: 490-495
23. Minor T, Akbar S, Tolba R et al. Cold preservation of fatty liver grafts: prevention of functional and ultrastructural impairments by venous oxygen persufflation. J hepatol 2000; 32: 105-111
24. Smyrniotis V, Kostapanagiotou G, Lolis E et al. Effects of hepatovenous back flow on ischemic reperfusion injuris in liver resection with the pringle maneuver. J Am Coll Surg 2003; 197: 949-954
25. Pringle JH. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg 1908; 48: 541-549
26. Pestieau SR, Belliveau JF, Griffin H et al. Pharmacokinetics of intraperitoneal Oxaliplatin: Experimental Studies. J Surg Oncol 2001; 76: 106-114
27. Yonezawa K, Tolba RH, Wetter A et al. L-carnitine could not improve hepatic warm ischemia-reperfusion injury despite ameliorated blood flow. J Surg Res 2005; 125: 16-22
28. Minor T, Manekeller S. Assessment of hepatic integrity after ischemic preservation by isolated perfusion in vitro: The role of albumin. Cryobiology 2007; 54: 188-195
29. Minor T, Kötting M. Gaseous Oxygen for Hypothermic Preservation of Predamaged Grafts: Fuel to Cellular Homeostasis or Radical Tissue Alteration? Cryobiology 2000; 40: 182-186
30. Reimertz C, Kögel D, Rami A et al. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J Cell Biol 2003; 18: 587-597
31. Rao RV, Peel A, Logvinova A et al. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Letters 2002; 514: 122-128
32. Imber CJ, Peter SDSt, Cenarruzabeitia IL et al. Optimisation of bile production during normothermic preservation of porcine livers. Am J Transplant 2002; 2: 593-599
33. Zorzi D, Laurent A, Pawlik TM et al. Chemotherapy-associated hepatotoxity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274-286
34. Szegezdi E, Fitzgerald U, Samali A. Caspase12 and ER-stress-mediated apoptosis, the Story so far. Ann NY Acad Sci 2003; 1010: 186-194
35. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol 2004; 14: 20-28
36. Budihardjo I, Holt O, Lutter M et al. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15: 269-290